Ask about this productRelated genes to: SHBG antibody
- Gene:
- SHBG NIH gene
- Name:
- sex hormone binding globulin
- Previous symbol:
- -
- Synonyms:
- ABP, TEBG, MGC126834, MGC138391
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-14
- Date modifiied:
- 2016-04-04
Related products to: SHBG antibody
Related articles to: SHBG antibody
- Pubertal gynecomastia (PG) is a benign condition considered to be caused by imbalance between estrogen and testosterone, though this is not frequently evident from serum analysis. This study aimed to determine possible alteration in sex hormone levels, as well as to investigate the role of sex hormone-binding globulin (SHBG) and leptin in PG development and persistence. - Source: PubMed
Publication date: 2026/08/31
Todorova Zdravka PetrovaZdravkov Blagomir Nikolaev - To evaluate the association of serum irisin, together with reproductive endocrine and metabolic indicators, with clinical pregnancy outcomes following fertilization and embryo transfer (IVF-ET) in women with polycystic ovary syndrome (PCOS). - Source: PubMed
Publication date: 2026/08/14
Wang HuixiaSu ChunlinJin WeiLu WeiweiBi TingtingCheng QilinJi Dongmei - Benzophenones (BPs), widely used UV filters and endocrine disruptors globally known for their estrogenic effects, are raising growing concerns about chronic reproductive toxicity in males due to their increasing environmental concentrations. This study aims to reveal the effects and mechanisms of male reproductive injury induced by environmentally relevant concentrations of BPs exposure. - Source: PubMed
Publication date: 2026/08/25
Li Hong-MeiKou Ju-QinPu Ya-JiaWang QianSheng Yu-XinWang Jun-ZeTian Ya-NanGao Yan-RongSun Jia-HeZeng Xiao-QiXu Hai-Ming - Infertility is a major global health burden, yet scalable lifestyle strategies to improve reproductive outcomes remain limited. Exercise is low cost and biologically plausible, but evidence on its association with fertility-related outcomes is dispersed across multiple meta-analyses. We therefore conducted an umbrella review of meta-analyses of randomised controlled trials evaluating exercise and fertility-related outcomes in females and males. - Source: PubMed
Publication date: 2026/08/28
Lam Lai KwanAlemu Bekalu KassieDavenport Margie HWang Chi ChiuChan Yiu LeungWang Yao - Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic-pituitary-gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, infertility, polycystic ovary syndrome (PCOS), impaired endometrial receptivity, and adverse pregnancy outcomes. Central obesity and insulin resistance contribute to hyperinsulinemia, reduced sex hormone-binding globulin (SHBG) levels, hyperandrogenism, altered gonadotropin secretion, and impaired folliculogenesis, while adipokines such as leptin and chronic inflammation further impair ovarian steroidogenesis and ovulatory function. Obesity-related oxidative stress and lipotoxicity also negatively affect oocyte quality, embryo development, implantation, and assisted reproductive technology outcomes, increasing the risk of gestational diabetes, preeclampsia, miscarriage, and preterm birth. This review evaluates the therapeutic potential of pharmacological weight-loss therapies in obesity-associated female reproductive dysfunction. A comprehensive literature review was conducted using various databases, focusing on anti-obesity pharmacotherapy on obesity, infertility and fertility in reproductive-aged women. Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily indirectly through weight reduction and metabolic improvement. GLP-1 receptor agonists, particularly liraglutide, semaglutide, and exenatide, appear especially promising, demonstrating beneficial effects on insulin sensitivity, menstrual regularity, ovulation, androgen levels, and pregnancy rates in women with PCOS. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits. Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial. However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required. - Source: PubMed
Publication date: 2026/07/25
Varra Fani-NikiTheodosis-Nobelos PanagiotisVarra Viktoria-KonstantinaVarras Michail